Celyad: USPTO issues a patent on Allogeneic TCR-deficient CAR T-Cell
BUY, Fair Value EUR71
AstraZeneca: Today’s FDA AdCom expected to act on lesinurad
BUY, Fair Value 5100p (+27%)
Q3 15 analysts' meeting and conference call feedback: valuation still demanding
SELL, Fair Value EUR60 vs. EUR61 (-13%)
Sword Group: Q3 15 results in line after two asset disposals, FY15 guidance will be exceeded
BUY, Fair Value EUR25 (+8%)
Genomic Vision: Genomic Vision's Q3 sales
CORPORATE, Fair Value EUR23
Pernod Ricard: A good start to the year
BUY, Fair Value EUR120 (+16%)
bioMérieux: Good Q3 performance. Declining China leads to a shy upward revision in guidance
BUY, Fair Value EUR108 vs. EUR107 (+7%)
Roche raises its outlook as momentum lasts after Q3 stronger base
BUY-Top Picks, Fair Value CHF327 (+29%)
Saint Gobain: Good Q3 for Roofing Peer Owens Corning
BUY, Fair Value EUR50 (+33%)